ES2494015T3 - Composiciones para tratar nauseas y vómitos de origen central - Google Patents
Composiciones para tratar nauseas y vómitos de origen central Download PDFInfo
- Publication number
- ES2494015T3 ES2494015T3 ES10805301.8T ES10805301T ES2494015T3 ES 2494015 T3 ES2494015 T3 ES 2494015T3 ES 10805301 T ES10805301 T ES 10805301T ES 2494015 T3 ES2494015 T3 ES 2494015T3
- Authority
- ES
- Spain
- Prior art keywords
- vomiting
- administered
- nausea
- patient
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010047700 Vomiting Diseases 0.000 title abstract description 10
- 239000000203 mixture Substances 0.000 title 1
- WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 abstract description 6
- 229960005163 netupitant Drugs 0.000 abstract description 5
- 230000001154 acute effect Effects 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 2
- 229960003957 dexamethasone Drugs 0.000 abstract 2
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 abstract 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 abstract 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 abstract 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 210000001577 neostriatum Anatomy 0.000 abstract 1
- 230000001839 systemic circulation Effects 0.000 abstract 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 4
- 229960002131 palonosetron Drugs 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940029320 netupitant 300 mg Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Paints Or Removers (AREA)
Abstract
Una combinación de (i) netupitant o una sal farmacéuticamente aceptable del mismo, (ii) un antagonista de 5-HT3 o una sal farmacéuticamente aceptable del mismo, (iii) dexametasona, para su uso en el tratamiento de náuseas y vómitos durante cinco días consecutivos en un paciente que lo necesita, en la que: a) se administra dicho netupitant o una sal farmacéuticamente aceptable del mismo a dicho paciente el día uno, en una cantidad terapéuticamente eficaz que es eficaz para tratar náuseas y vómitos durante las fases aguda y tardía de emesis, y que entra en la circulación sistémica, cruza la barrera hematoencefálica y ocupa al menos el 70 % de receptores NK1 en el cuerpo estriado setenta y dos horas después de dicha administración; b) se administra el antagonista de 5-HT3 o una sal farmacéuticamente aceptable del mismo a dicho paciente el día uno, en una cantidad terapéuticamente eficaz, que es eficaz para tratar náuseas y vómitos durante las fases aguda y tardía; y c) se administra dexametasona a dicho paciente el día uno en una primera dosis que es ineficaz contra náuseas y vómitos cuando se administra sola, pero eficaz contra náuseas y vómitos cuando se administra en combinación con dicho netupitant, en la que la primera dosis comprende del 50 al 70 % de una dosis eficaz mínima cuando se administra sola.
Description
E10805301
12-08-2014
• Gravedad de las náuseas para la fase global, aguda y tardía; • Satisfacción global del paciente con el tratamiento antiemético por medio de VAS para cada intervalo de 24 horas.
Las tasas de respuesta completa se resumen en la tabla 5. El porcentaje de pacientes con respuesta completa sobre 0-120 horas después del inicio de la administración de cisplatino fue del 76,5 % en el grupo de palonosetrón solo y del 87,4 %, 87,6 %, y del 89,6 % en los grupos de netupitant 100 mg, 200 mg, y 300 mg, respectivamente. Las diferencias de palonosetrón solo fueron mayores del 10 % (del 10,9 % al 13,2 %). Todas las dosis de netupitant fueron estadísticamente superiores a palonosetrón solo (valor p = 0,004 para el grupo de combinación de netupitant 300 mg).
Tabla 5: Tasa de respuesta completa para la fase global, aguda y tardía: Población MFAS
- Criterio de valoración de eficacia
- Palo solo (n=136) Palo + Netu 100 mg (n=135) Palo + Netu 200 mg (n=137) Palo + Netu 300 mg (n=135) Régimen de aprepitant (N=134)
- RC, fase global, 0-120 h
- Porcentaje de pacientes
- 76,5 87,4 87,6 89,6 86,6
- Diferencia de Palo solo (%)
- 10,9 11,1 13,2 10,1
- Valor p (*)
- 0,018 0,017 0,004 0,027
- RC, fase aguda, 0-24 h
- Porcentaje de pacientes
- 89,7 93,3 92,7 98,5 94,8
- Diferencia de Palo solo (%)
- 3,6 3,0 8,8 5,1
- Valor p (*)
- 0,278 0,383 0,007 0,114
- RC, fase tardía, 25-120 h
- Porcentaje de pacientes
- 80,1 90,4 91,2 90,4 88,8
- Diferencia de Palo solo (%)
- 10,2 11,1 10,2 8,7
- Valor p (*)
- 0,018 0,010 0,018 0,043
(*) valor p del análisis de regresión logística, valor p de aprepitant del análisis de regresión logística a posteriori.
10 La tabla 6 resume los principales criterios de valoración secundarios. En la fase global, el 76,5 % de los pacientes en el grupo de palonosetrón solo no experimentó emesis, mientras que el 87,4, 87,6, y 91,1 % de los pacientes no experimentó emesis en los grupos de combinación de netupitant 100 mg, 200 mg y 300 mg, respectivamente (p<0,05 para todas las dosis).
Tabla 6: Resumen de los resultados de eficacia secundaria: porcentaje de pacientes. Población MFAS
- Criterio de valoración de eficacia
- Palo solo (n=136) Palo + Netu 100 mg (n=135) Palo + Netu 200 mg (n=137) Palo + Netu 300 mg (n=135) Régimen de aprepitant (N=134) Palo + Aprep 285 mg (N=41) **
- Sin emesis
- Global
- 76,5 87,4* 87,6* 91,1* 87,3*
- Aguda
- 89,7 93,3 92,7 98,5* 94,8
- Tardía
- 80,1 90,4* 91,2* 91,9* 89,6*
- Sin rescate
- Global
- 95,6 97,8 100 98,5 97,8
- Aguda
- 97,8 99,3 100 100 100
- Tardía
- 97,1 97,8 100 98,5 97,8
- Sin náuseas
- Global
- 50,7 54,8 62,0 61,5 58,2 32
- Aguda
- 75,0 72,6 77,4 80,0 77,6 59
- Tardía
- 53,7 59,3 65,0 68,1* 60,4 41
- Sin náuseas significativas
- Global
- 79,4 80,0 86,1 89,6* 85,8 56
- Aguda
- 93,4 94,1 94,2 98,5* 94,0 79
- Tardía
- 80,9 81,5 89,8* 90,4* 88,1 59
- Control total
- Global
- 50,0 54,8 61,3 59,3 56,0
- Aguda
- 71,3 71,9 76,6 80,0 74,6
- Tardía
- 52,2 59,3 65,0* 65,9* 58,2
- Protección completa
- Global
- 69,9 76,3 80,3* 83,0* 78,4 51
- Aguda
- 87,5 89,6 88,3 97,0* 89,6 76
14
Claims (1)
-
imagen1 imagen2 imagen3 imagen4
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26247009P | 2009-11-18 | 2009-11-18 | |
| US262470P | 2009-11-18 | ||
| US38270910P | 2010-09-14 | 2010-09-14 | |
| US382709P | 2010-09-14 | ||
| PCT/IB2010/003106 WO2011061622A1 (en) | 2009-11-18 | 2010-11-18 | Compositions for treating centrally mediated nausea and vomiting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2494015T3 true ES2494015T3 (es) | 2014-09-12 |
Family
ID=43608757
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14151678.1T Active ES2623503T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos mediados centralmente |
| ES10805301.8T Active ES2494015T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar nauseas y vómitos de origen central |
| ES14151676.5T Active ES2559475T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos de origen central |
| ES14151683.1T Active ES2595077T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos mediados centralmente |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14151678.1T Active ES2623503T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos mediados centralmente |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14151676.5T Active ES2559475T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos de origen central |
| ES14151683.1T Active ES2595077T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos mediados centralmente |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US12042494B2 (es) |
| EP (3) | EP2722044B1 (es) |
| JP (1) | JP5890780B2 (es) |
| KR (1) | KR101615108B1 (es) |
| CN (6) | CN106512010A (es) |
| AP (1) | AP3083A (es) |
| AU (1) | AU2010320598B2 (es) |
| BR (1) | BR112012011485B1 (es) |
| CA (1) | CA2778301C (es) |
| CL (1) | CL2012001276A1 (es) |
| CO (1) | CO6551693A2 (es) |
| CR (1) | CR20120216A (es) |
| CU (1) | CU24048B1 (es) |
| CY (1) | CY1118062T1 (es) |
| DK (2) | DK2361090T3 (es) |
| DO (1) | DOP2012000138A (es) |
| EA (1) | EA026815B1 (es) |
| EC (1) | ECSP12011907A (es) |
| ES (4) | ES2623503T3 (es) |
| GE (1) | GEP20156226B (es) |
| GT (1) | GT201200156A (es) |
| HK (2) | HK1214147A1 (es) |
| HR (3) | HRP20140759T1 (es) |
| HU (1) | HUE029677T2 (es) |
| IL (1) | IL219576A (es) |
| LT (1) | LT2722045T (es) |
| MA (1) | MA33810B1 (es) |
| MX (1) | MX2012005347A (es) |
| MY (1) | MY159393A (es) |
| NI (1) | NI201200090A (es) |
| NZ (1) | NZ599439A (es) |
| PE (1) | PE20121483A1 (es) |
| PL (3) | PL2722044T3 (es) |
| PT (2) | PT2361090E (es) |
| RS (2) | RS55206B1 (es) |
| SI (2) | SI2722045T1 (es) |
| SM (1) | SMT201400112B (es) |
| TN (1) | TN2012000170A1 (es) |
| WO (1) | WO2011061622A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| ES2623503T3 (es) | 2009-11-18 | 2017-07-11 | Helsinn Healthcare Sa | Composiciones para tratar náuseas y vómitos mediados centralmente |
| WO2013004766A1 (en) * | 2011-07-04 | 2013-01-10 | Ferrari Giulio | Nk-1 receptor antagonists for treating corneal neovascularisation |
| EP2759298B1 (en) * | 2011-10-18 | 2018-01-17 | Helsinn Healthcare SA | Therapeutic combinations of netupitant and palonosetron |
| US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| US9403772B2 (en) | 2011-11-29 | 2016-08-02 | Helsinn Healthcare Sa | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
| CN103520725B (zh) * | 2012-07-05 | 2017-10-24 | 海思科医药集团股份有限公司 | 一种治疗呕吐的药物组合物 |
| CN106902086B (zh) * | 2015-12-23 | 2020-10-20 | 江苏恒瑞医药股份有限公司 | 一种包含奈妥匹坦的固体组合物 |
| GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| CN108721214B (zh) * | 2017-04-14 | 2020-06-16 | 和龙 | 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途 |
| CN108853010A (zh) * | 2017-05-15 | 2018-11-23 | 和龙 | 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途 |
| CN109200018A (zh) * | 2017-07-04 | 2019-01-15 | 南京诺瑞特医药科技有限公司 | 含有奈妥吡坦的微乳制剂 |
| AU2018367623B2 (en) * | 2017-11-17 | 2024-03-28 | Vanda Pharmaceuticals Inc. | Method of treatment of gastrointestinal diseases with tradipitant |
| AU2019215802A1 (en) * | 2018-02-02 | 2020-07-23 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Oral formulations and uses thereof |
| WO2024126398A1 (en) | 2022-12-12 | 2024-06-20 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Fixed dose combination comprising netupitant and palonosetron |
| EP4385500A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Fixed dose combination comprising netupitant and palonosetron |
| WO2024126408A1 (en) | 2022-12-12 | 2024-06-20 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
| EP4385497A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA909529B (en) | 1989-11-28 | 1992-08-26 | Syntex Inc | New tricyclic compounds |
| US5510486A (en) | 1994-07-26 | 1996-04-23 | Syntex (U.S.A.) Inc. | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one |
| US6297395B1 (en) | 1995-11-10 | 2001-10-02 | The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Calixarenes and their use for sequestration of metals |
| EP1035115B1 (en) | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| KR100501608B1 (ko) | 2000-07-14 | 2005-07-18 | 에프. 호프만-라 로슈 아게 | 4-페닐-피리딘 유도체의 ｎｋ1 수용체의 길항성선구약물로서의 ｎ-산화물 |
| KR100602299B1 (ko) | 2000-12-14 | 2006-07-14 | 에프. 호프만-라 로슈 아게 | 자가 유화성 지질 매트릭스 |
| AU2003302072A1 (en) | 2002-11-15 | 2004-06-15 | Helsinn Healthcare Sa | Palonosetron for the treatment of chemotherapy-induced emesis |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| MY143789A (en) * | 2003-02-18 | 2011-07-15 | Helsinn Healthcare Sa | Use of palonosetron treating post- operative nausea and vomiting |
| MXPA05010819A (es) * | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable. |
| BRPI0606187A2 (pt) | 2005-02-25 | 2009-06-09 | Hoffmann La Roche | comprimidos com capacidade de dispersão da substáncia do fármaco melhorada |
| US7479312B2 (en) | 2005-07-07 | 2009-01-20 | Konica Minolta Opto, Inc. | Retardation film, polarizing plate, and liquid crystal display device |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| WO2007096763A2 (en) | 2006-02-23 | 2007-08-30 | Pfizer Limited | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
| EP1940366B9 (en) * | 2006-10-24 | 2009-12-02 | Helsinn Healthcare S.A. | Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability |
| US20110014117A1 (en) * | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
| US20110091524A1 (en) * | 2007-12-18 | 2011-04-21 | Yan Wang | Biomarkers for sensitivity to anti-igf1r therapy |
| ES2623503T3 (es) | 2009-11-18 | 2017-07-11 | Helsinn Healthcare Sa | Composiciones para tratar náuseas y vómitos mediados centralmente |
-
2010
- 2010-11-18 ES ES14151678.1T patent/ES2623503T3/es active Active
- 2010-11-18 KR KR1020127015676A patent/KR101615108B1/ko active IP Right Grant
- 2010-11-18 PL PL14151678T patent/PL2722044T3/pl unknown
- 2010-11-18 MY MYPI2012002073A patent/MY159393A/en unknown
- 2010-11-18 CN CN201610797549.7A patent/CN106512010A/zh active Pending
- 2010-11-18 RS RS20160833A patent/RS55206B1/sr unknown
- 2010-11-18 PL PL10805301T patent/PL2361090T3/pl unknown
- 2010-11-18 CN CN2010800521070A patent/CN102655864A/zh active Pending
- 2010-11-18 PT PT108053018T patent/PT2361090E/pt unknown
- 2010-11-18 AU AU2010320598A patent/AU2010320598B2/en active Active
- 2010-11-18 BR BR112012011485-9A patent/BR112012011485B1/pt active IP Right Grant
- 2010-11-18 ES ES10805301.8T patent/ES2494015T3/es active Active
- 2010-11-18 PL PL14151683T patent/PL2722045T3/pl unknown
- 2010-11-18 HU HUE14151683A patent/HUE029677T2/hu unknown
- 2010-11-18 DK DK10805301.8T patent/DK2361090T3/da active
- 2010-11-18 PE PE2012000686A patent/PE20121483A1/es active IP Right Grant
- 2010-11-18 CN CN201610795827.5A patent/CN106421793B/zh active Active
- 2010-11-18 NZ NZ599439A patent/NZ599439A/en unknown
- 2010-11-18 CN CN201610795817.1A patent/CN107050455B/zh active Active
- 2010-11-18 ES ES14151676.5T patent/ES2559475T3/es active Active
- 2010-11-18 SI SI201031291T patent/SI2722045T1/sl unknown
- 2010-11-18 MX MX2012005347A patent/MX2012005347A/es active IP Right Grant
- 2010-11-18 RS RSP20140423 patent/RS53491B1/en unknown
- 2010-11-18 ES ES14151683.1T patent/ES2595077T3/es active Active
- 2010-11-18 PT PT141516831T patent/PT2722045T/pt unknown
- 2010-11-18 CA CA2778301A patent/CA2778301C/en active Active
- 2010-11-18 WO PCT/IB2010/003106 patent/WO2011061622A1/en active Application Filing
- 2010-11-18 JP JP2012539433A patent/JP5890780B2/ja active Active
- 2010-11-18 CN CN201510046972.9A patent/CN104856998A/zh active Pending
- 2010-11-18 DK DK14151683.1T patent/DK2722045T3/en active
- 2010-11-18 EP EP14151678.1A patent/EP2722044B1/en active Active
- 2010-11-18 AP AP2012006278A patent/AP3083A/xx active
- 2010-11-18 EA EA201290356A patent/EA026815B1/ru active Protection Beyond IP Right Term
- 2010-11-18 SI SI201030688T patent/SI2361090T1/sl unknown
- 2010-11-18 GE GEAP201012752A patent/GEP20156226B/en unknown
- 2010-11-18 LT LTEP14151683.1T patent/LT2722045T/lt unknown
- 2010-11-18 EP EP10805301.8A patent/EP2361090B1/en active Active
- 2010-11-18 CN CN201510047631.3A patent/CN104856999A/zh active Pending
- 2010-11-18 EP EP14151676.5A patent/EP2727590B1/en active Active
-
2012
- 2012-04-13 TN TNP2012000170A patent/TN2012000170A1/en unknown
- 2012-04-26 CR CR20120216A patent/CR20120216A/es unknown
- 2012-05-03 IL IL219576A patent/IL219576A/en active IP Right Grant
- 2012-05-10 NI NI201200090A patent/NI201200090A/es unknown
- 2012-05-15 DO DO2012000138A patent/DOP2012000138A/es unknown
- 2012-05-16 CL CL2012001276A patent/CL2012001276A1/es unknown
- 2012-05-17 EC ECSP12011907 patent/ECSP12011907A/es unknown
- 2012-05-18 CU CU2012000078A patent/CU24048B1/es active IP Right Grant
- 2012-05-18 CO CO12082329A patent/CO6551693A2/es not_active Application Discontinuation
- 2012-05-18 GT GT201200156A patent/GT201200156A/es unknown
- 2012-06-11 MA MA34953A patent/MA33810B1/fr unknown
-
2014
- 2014-08-11 HR HRP20140759AT patent/HRP20140759T1/hr unknown
- 2014-08-18 SM SM201400112T patent/SMT201400112B/xx unknown
-
2016
- 2016-02-24 HK HK16102109.6A patent/HK1214147A1/zh unknown
- 2016-02-24 HK HK16102110.3A patent/HK1214148A1/zh unknown
- 2016-10-05 HR HRP20161277TT patent/HRP20161277T1/hr unknown
- 2016-10-05 CY CY20161100991T patent/CY1118062T1/el unknown
-
2017
- 2017-03-14 HR HRP20170419TT patent/HRP20170419T1/hr unknown
-
2022
- 2022-12-16 US US18/082,737 patent/US12042494B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2494015T3 (es) | Composiciones para tratar nauseas y vómitos de origen central | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| ES2866933T3 (es) | Regímenes de dosificación de amisulprida para tratar náuseas y vómitos | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2018505882A5 (es) | ||
| AR085934A1 (es) | Tratamiento de mieloma multiple con masitinib | |
| AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
| JP2012502047A5 (es) | ||
| RU2015102831A (ru) | ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α, 25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА | |
| RU2017128616A (ru) | Комбинированное лекарственное средство | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2020500864A5 (es) | ||
| CO2022008437A2 (es) | Métodos de tratamiento del cáncer de pulmón de cé-lulas pequeñas con formulaciones de lurbinectedina | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2016505050A5 (es) | ||
| Collaborative Group of the Spanish Society of Clinical Pharmacology et al. | Comparative study of the efficacy of dipyrone, diclofenac sodium and pethidine in acute renal colic | |
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| JP2019509309A5 (es) | ||
| JP2016515137A5 (es) | ||
| CA2829130A1 (en) | Ezatiostat for treating multiple myeloma |